UCB

“Candid Therapeutics... Acquired by UCB for up to $2.2B”

“UCB agreed to acquire Candid Therapeutics, a San Diego-based autoimmune biotech that had raised $370m.”

“Candid had previously agreed to a reverse merger with Rallybio, but says that UCB made a superior offer.”